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Pathogenesis
Actinomycosis is a chronic suppurative granulomatous
disease caused by Actinomyces spp. (mostly A. israelii),
which are anaerobic or slightly aerobic gram-positive rods
normally inhabiting the oral cavity, gastrointestinal tract
and female genital tract. Tissue lesions form abscesses and
ﬁstulae, with sulfur granules (drusen) found in pus. Acti-
nomyces species are normally not pathogenic, but invade
tissues via mucous membranes damaged by inﬂammatory
changes or trauma and thereby establish inﬂammation. The
lesions eventually become tumorous and are often mis-
diagnosed as tumors.
Actinomycosis involves the facial and cervical region in
40–60% of patients, the abdominal region in 20–30%, and
the thoracic region in 10–20% [1]. In rare cases, hema-
togenous dissemination causes involvement of multiple
organs, resulting in multiple nodular lesions. Actinomy-
cosis of the female genital tract usually occurs in women
who have used intrauterine device (IUD) contraceptives for
2–3 years or more. It forms a pelvic mass or a tubo-ovarian
abscess, which can be confused with an ovarian tumor.
However, in most cases, there are positive inﬂammatory
ﬁndings such as high white blood cell (WBC) counts and
high levels of C-reactive protein (CRP); and thus, a diag-
nosis of pelvic inﬂammatory disease (PID) can be made
based on these ﬁndings in addition to subjective
symptoms [2].
Pathogen
Although A. israelii is the most common cause of actino-
mycosis, A. naeslundii, A. viscosus and Propionibacterium
propionicum can also cause this disease, though at lower
frequencies (Table 1) [3].
Colonies of Actinomyces spp. vary in shape, ranging
from round and elevated to molar. Overnight culture may
produce spider-like micro-colonies. Actinomyces cells
show various structures, such as long ﬁlamentous, short,
straight or curved rods. Short rods are diphtheroids having
crab claw-like tips. Short-chain or nubbly arrangements are
characteristic. Branching long rods may also be seen.
Although actinomycetes, excluding A. meyeri, can grow to
some extent in CO2 culture, anaerobic culture is most
suitable for isolating these bacteria.
Table 1 Causative organism of actinomycosis
Organism No. of isolates Proportion (%)
Actinomyces israeliia 1,009 73.3
A. gerencseriaea 28 2.0
A. naeslundii 94 6.8
A. viscosus 68 4.9
A. odontolyticus 19 1.4
A. meyeri 8 0.6
A. georgiae 2 0.2
A. neuii 2 0.2
Propionibacterium propionicum 46 3.3
Biﬁdobacterium dentium 5 0.4
Corynebacterium matruchotii 12 0.9
Rothia dentocariosa 5 0.4
Not identiﬁable 78 5.7
Total 1,376 100.0
Cases related to IUD use were excluded (modiﬁed from Ref. 3)
a A. israelii and A. gerencseriae were classiﬁed as the same species
until 1987
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Diagnosis
To establish a diagnosis of actinomycosis, separated
identiﬁcation of actinomycetes and detection of charac-
teristic sulfur granules (drusen) from pus or tissue samples
is necessary. However, separated identiﬁcation of actino-
mycetes is extremely difﬁcult. Therefore, actinomycosis is
diagnosed in most cases on the basis of identiﬁcation of
sulfur particles by histopathological examination.
Examination of smears taken from the uterine cervix or
corpus provides some basis for a diagnosis of pelvic
infection with actinomycetes in women using an IUD [2].
Antimicrobial therapy
Prolonged high-dose therapy with penicillins is necessary
for the treatment of this disease. In general, 2–6 weeks of
parenteral administration should be followed by oral
administration to complete a full 6- to 12-month course of
treatment. If the patient is allergic to penicillins, tetracy-
cline (TC), macrolides or lincomycin (LCM), etc. can be
administered (Table 2). In Japan, only benzylpenicillin
(PCG) and ampicillin (ABPC) are covered by health
insurance. Some cases may require treatment of co-infec-
tions with other pathogens. In most cases, however, sufﬁ-
cient treatment for the Actinomyces infection reportedly
cures actinomycosis, without treatment of the coexisting
pathogens.
Surgical procedures such as incision, drainage and
resection, combined with medications, are reportedly
effective. It is said that surgical reduction allows the total
treatment period to be shortened to 3–6 months [4].
However, reports of cases cured with medical treatment
alone have been increasing in recent years. Therefore, it is
recommended that suspected patients with actinomycosis
receive ﬁrst-line penicillin therapy, and that surgical pro-
cedures be added to this medical therapy if the disease is
refractory to medications.
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Table 2 Therapeutic agents for actinomycosis
Penicillins
Benzylpenicillin 1,200,000–2,400,000 units/day 2–4 divided doses Intramuscular
10,000,000–20,000,000 units/day 4–6 divided doses Intravenousa
Piperacillin 4 g/day 2 divided doses Intravenous
Ampicillin 2 g/day 2 divided doses Intravenous
1 g/day 2–4 divided doses Intramuscular
750–1,000 mg/day 3-4 divided doses Oral
Amoxicillin 750–1,000 mg/day 3–4 divided doses Oral
Tetracyclines
Doxycycline 200 mg/day 1–2 divided doses Intravenous or oral
Minocycline 200 mg/day 2 divided doses Intravenous or oral
Macrolides
Erythromycin 2–4 g/day 4 divided doses Intravenous
1–2 g/day 4 divided doses Oral
Lincomycins
Clindamycin 2.4 g/day 2–3 divided doses Intravenous
1.2–1.8 g/day 3–4 divided doses Oral
a Intravenous route is used in the US
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